Clinical Trials
Below are current clinical trials.
271 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of investigational drug versus placebo in adults with primary (first episode) Clostridium difficile infection (CDI).
-
Scottsdale/Phoenix, Ariz.
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to measure the rates of continuing viral presence, following anti-viral therapy with combined Peg-Interferon and Ribavirin in patients that have had a liver transplant, are immune suppressed with Neoral or tacrolimus, and have a recurring infection with the Hepatitis C virus.
-
Rochester, Minn.
The purpose of this study is to study HIV infected individuals or others who have had another infection or inflammatory condition that may affect the content or structure of lymph nodes or may have none of these conditions and the sample will be used as a normal control.
-
Rochester, Minn.
The purpose of this registry is to enroll patients who have cirrhosis with a sustained viral response after receiving a sofosbuvir-based treatment without interferon, either while participating in a Gilead-sponsored hepatitis C virus study or commercially at selected sites. Once enrolled, the patients will be followed for up to 5 years.
-
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of this study is to demonstrate the tests' performance when compared to the detection of periprosthetic joint infection (PJI) using the Musculoskeletal Infection Society (MSIS) criteria-based definition of PJI for diagnosing PJI. This criteria-based definition of PJI places emphasis on culture techniques that identify pathogens, but also provides for minor criteria that can be used to diagnose PJI. This study will also calculate the tests' clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV).
-
Rochester, Minn.
To compare the efficacy of brincidofovir (BCV) to valganciclovir (vGCV) for the prevention of cytomegalovirus (CMV) disease in kidney transplant allograft recipients who are CMV seronegative pretransplant and received a kidney from a CMV seropositive donor.
-
Rochester, Minn.
The purpose of this study is to compare the performance of the FilmArray Respiratory Panel in nasopharyngeal (NP) swabs and bronchoalveolar lavage (BAL) fluid collected from immunocompromised hosts (ICH).
-
Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to describe the clinicopathological features and characterize the genetic variants (by Whole exome sequencing).
-
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT for patients with chemotherapy-sensitive hematological malignancies and coincident HIV-infection. In particular, the trial will focus on the 100-day non-relapse mortality as an indicator of the safety of transplant in this patient population. Correlative assays will focus upon the incidence of infectious complications in this patient population, the evolution of HIV infection and immunological reconstitution. Where feasible (and when this can be accomplished without compromise of either the donor quality or the timeliness of transplantation), an attempt will be made to identify donors who are homozygotes for the delta32 mutation for CCR5.